A positive interim readout will be much higher than 50c. - Only...

A positive interim readout will be much higher than 50c.

1. - Only drug in Phase 3 study for FSGS after sparsentan failure
2. - Different mechanism of action than sparsentan
3. - Placebo-controlled study design
4. - FSGS leads to kidney failure, dialysis, or transplant - There are NO approved drugs specifically for FSGS
5. - High recurrence rate in transplanted kidneys
6. - Increased licensing partner interest,
7. - Estimated FSGS market of over $3 billion per annum by 2030 - Attractive market in seven major markets - Large unmet need in China
8. - Patent applications in progress in key jurisdictions
9. - Exclusivity for DMX-200 until at least 2036
10. - Received Orphan Drug Designation with the FDA, EMA, and UK, allowing potential fast-track commercialisation if successful.

To quote Nina verbatim from shareholders webinar 04/05/23:

"Dimerix has no plans to take the drug to market itself, and we will ultimately commercialize with a partner. Our preference is to work with partners that have strong sales and marketing infrastructure and experience. We have received a significant amount of interest from global pharma companies since we started our Phase 3 trial."

Advanz pharma offering > $220M in milestone payments alone just for EU, Canada and ANZ!
Significant unmet need in the US and China markets.